The impact of ibuprofen or indomethacin on renal drug clearance in neonates

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 22, Issue SUPPL. 3, 2009, Pages 88-91

  Allegaert, Karel ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Amikacin; Ibuprofen; Indomethacin; Patent ductus arteriosus; Vancomycin

Indexed keywords

ACETYLSALICYLIC ACID; AMIKACIN; IBUPROFEN; INDOMETACIN; VANCOMYCIN;

ARTICLE; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; GESTATIONAL AGE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY CLEARANCE; KIDNEY FUNCTION; PREMATURITY; PRIORITY JOURNAL;

AMIKACIN; ANTI-BACTERIAL AGENTS; CYCLOOXYGENASE INHIBITORS; DRUG INTERACTIONS; GLOMERULAR FILTRATION RATE; HUMANS; IBUPROFEN; INDOMETHACIN; INFANT, NEWBORN; KIDNEY; METABOLIC CLEARANCE RATE; VANCOMYCIN;

EID: 70449397274     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.1080/14767050903180965     Document Type: Article

References (11)

1. Cuzzolin L, Fanos V, Pinna B, di Marzio M, Perin M, Tramontozzi P, Tonetto P, Cataldi L. Postnatal renal function in preterm newborns: a role of diseases, drugs and therapeutic interventions. Pediatr Nephrol 2006;21:931-938.
2. Van Overmeire B, Chemtob S. The pharmacologic closure of the patent ductus arteriosus. Semin Fetal Neonatal Med 2005; 10:177-184.
3. Fanos V, Benini D, Verlato G, Errico G, Cuzzolin L. Efficacy and renal tolerability of ibuprofen vs. indomethacin in preterm infants with patent ductus arteriosus. Fundam Clin Pharmacol 2005;19:187-193.
4. Thomas RL, Parker GC, van Overmeire B, Aranda JV. A meta-analysis of ibuprofen versus indomethacin for closure of patent ductus arteriosus. Eur J Pediatr 2005;164:135-140.
5. Allegaert K, Anderson BJ, Cossey V, Holford NH. Limited predictability of amikacin clearance in extreme premature neonates at birth. Br J Clin Pharmacol 2006;61:39-48.
6. Anderson BJ, Allegaert K, van den Anker JN, Cossey V, Holford NH. Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. Br J Clin Pharmacol 2007;63:75-84.
7. Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: modelling covariate effects. Eur J Pediatr 2006;165:819-829. (Pubitemid 44627767)
8. Allegaert K, Cossey V, Langhendries JP, Naulaers G, Vanhole C, Devlieger H, van Overmeire B. Effects of co-administration of ibuprofen-lysine on the pharmacokinetics of amikacin in preterm infants during the first days of life. Biol Neonate 2004;86:207-211.
9. Langhendries JP, Battisti O, Bertrand JM, Francois A, Kalenga M, Darimont J, Scalais E, Wallemacq P. Adaptation in neonatology of the once-daily concept of aminoglycoside administration: evaluation of a dosing chart for amikacin in an intensive care unit. Biol Neonate 1998;74:351-362.
10. Silva R, Reis E, Bispo MA, Almeida AM, Costa IM, Falcao F, Palminha JM, Falcao AC. The kinetic profile of vancomycin in neonates. J Pharm Pharmacol 1998;50:1255-1260.
11. Antonucci R, Cuzzolin L, Arceri A, Dessi A, Fanos V. Changes in urinary PGE2 after ibuprofen treatment in preterm infants with patent ductus arteriosus. Eur J Clin Pharmacol 2009;65:223-230.